[1] Lobo NA, Shimono Y, Qian D, et al. The biology of cancer stem cells.Annu Rev Cell Dev Biol. 2007;23:675-699.[2] Borovski T, De Sousa E Melo F, Vermeulen L,et al. Cancer stem cell niche: the place to be. Cancer Res. 2011;71(3): 634-649.[3] Moore KA, Lemischka IR. Stem cells and their niches. Science. 2006;311(5769):1880-1885.[4] Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters.Cancer Res. 2006;66(9):4553-4557.[5] Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell. 2007;1(6):607-611.[6] Konopleva M, Tabe Y, Zeng Z, et al. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist Updat. 2009; 12(4-5):103-113.[7] Sipkins DA, Wei X, Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment.Nature. 2005;435(7044):969-973.[8] De Toni F, Racaud-Sultan C, Chicanne G,et al. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia.Oncogene. 2006;25(22):3113-3122.[9] Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1): 69-82.[10] Brabletz T, Jung A, Reu S, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98(18):10356-10361.[11] Vermeulen L, De Sousa E Melo F, van der Heijden M, et al.Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5): 468-476.[12] Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1): 69-82.[13] Oishi K, Kamakura S, Isazawa Y, et al. Notch promotes survival of neural precursor cells via mechanisms distinct from those regulating neurogenesis.Dev Biol. 2004;276(1): 172-184.[14] Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors.Cancer Res. 2006;66(15):7445-7452.[15] Qin JZ, Stennett L, Bacon P, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas.Mol Cancer Ther. 2004;3(8):895-902.[16] Doubravská L, Símová S, Cermak L,et al. Wnt-expressing rat embryonic fibroblasts suppress Apo2L/TRAIL-induced apoptosis of human leukemia cells. Apoptosis. 2008;13(4): 573-587. [17] De Toni EN, Thieme SE, Herbst A,et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res. 2008;14(15): 4713-4718.[18] Lapham A, Adams JE, Paterson A, et al. The Bcl-w promoter is activated by beta-catenin/TCF4 in human colorectal carcinoma cells.Gene. 2009;432(1-2):112-117.[19] Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007;1(4):389-402.[20] Iliopoulos D, Hirsch HA, Wang G,et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011;108(4):1397-1402.[21] Prasad S, Ravindran J, Aggarwal BB. NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem. 2010;336 (1-2):25-37.[22] Guzman ML, Rossi RM, Karnischky L,et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood. 2005;105(11):4163-4169.[23] Neelakantan S, Nasim S, Guzman ML,et al. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1).Bioorg Med Chem Lett. 2009;19(15):4346-4349.[24] Bhowmick NA, Neilson EG, Moses HL.Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015): 332-337.[25] Moore KA, Lemischka IR.Stem cells and their niches. Science. 2006;311(5769):1880-1885.[26] Westhoff MA, Fulda S. Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat. 2009;12(4-5):127- 136.[27] Boucher MJ, Morisset J, Vachon PH, et al. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 2000;79(3):355-369.[28] Erler JT, Bennewith KL, Cox TR,et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.Cancer Cell. 2009;15(1): 35-44.[29] Møller HD, Ralfkjær U, Cremers N, et al. Role of fibulin-5 in metastatic organ colonization. Mol Cancer Res. 2011;9(5): 553-563.[30] Westhoff MA, Zhou S, Bachem MG,et al. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene. 2008;27(39): 5169-5181.[31] Bao S, Wu Q, Li Z,et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008;68(15): 6043-6048.[32] Petit I, Karajannis MA, Vincent L, et al. The microtubule- targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial- dependent cell death. Blood. 2008;111(4):1951-1961.[33] Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.Blood. 2009; 113(24):6215-6224.[34] Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell. 2010;7(2):150-161.[35] Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364(7):656-665.[36] Panchision DM.The role of oxygen in regulating neural stem cells in development and disease. J Cell Physiol. 2009; 220(3):562-568.[37] Semenza GL.Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732.[38] Wong CC, Gilkes DM, Zhang H, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation.Proc Natl Acad Sci U S A. 2011;108(39): 16369-16374.[39] Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008;13(3):206-220.[40] Mazumdar J, O'Brien WT, Johnson RS,et al. O2 regulates stem cells through Wnt/β-catenin signalling. Nat Cell Biol. 2010;12(10):1007-1013.[41] Yeung TM, Gandhi SC, Bodmer WF. Hypoxia and lineage specification of cell line-derived colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2011;108(11):4382-4387.[42] Heddleston JM, Li Z, McLendon RE,et al. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8(20):3274-3284.[43] Shroff EH, Snyder C, Chandel NS. Role of Bcl-2 family members in anoxia induced cell death.Cell Cycle. 2007;6(7): 807-809.[44] Chen N, Chen X, Huang R, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}.J Biol Chem. 2009;284(15):10004-10012.[45] Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells.Nature. 2009;458(7239):780-783.[46] Reinehr R, Becker S, Eberle A, et al. Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem. 2005;280(29):27179- 27194.[47] Kim YH, Jung EM, Lee TJ,et al. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species- mediated up-regulation of death receptor 5 and down- regulation of c-FLIP. Free Radic Biol Med. 2008;44(6): 1055-1068.[48] Kim S, Lee TJ, Leem J, et al. Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL. J Cell Biochem. 2008;104(3):895-907.[49] Shiozawa Y, Pedersen EA, Patel LR,et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia. 2010;12(2):116-127.[50] Shiozawa Y, Pedersen EA, Havens AM,et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011; 121(4):1298-1312. |